登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)
ClinicalTrials.gov 上登记的一项乳腺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07729956,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 75 岁;性别:仅女性
登记记录的入选字段
Pathologically confirmed recurrent or metastatic triple-negative breast cancer;
入选标准第 5 条
Toxicities from prior anti-tumor therapy must have recovered to ≤ Grade 1 as defined by NCI-CTCAE v6.0;
入选标准第 10 条
Received surgery, radical radiotherapy, or immunotherapy within 4 weeks before the first dose;
排除标准第 1 条
Prior treatment with other T-cell receptor-targeting agents (excluding PD-1/PD-L1);
排除标准第 3 条
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
入选标准第 4 条
Must have at least one measurable lesion as defined by RECIST v1.1;
入选标准第 9 条
Active malignancy diagnosed within 3 years before randomization;
排除标准第 10 条
HIV antibody positive, active HBV, or active HCV;
排除标准第 23 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07729956,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Voluntarily sign the informed consent form and agree to comply with the protocol requirements; Female patients aged 18 to 75 years; Expected survival time ≥ 3 months; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; Pathologically confirmed recurrent or metastatic triple-negative breast cancer; Confirmed PD-L1 expression positivity by central laboratory testing; No prior systemic anti-tumor therapy in the advanced/recurrent or metastatic setting; Agree to provide archived tumor tissue specimens (surgical specimens) or fresh tissue samples from primary or metastatic lesions obtained within 3 years; Must have at least one measurable lesion as defined by RECIST v1.1; Toxicities from prior anti-tumor therapy must have recovered to ≤ Grade 1 as defined by NCI-CTCAE v6.0; No severe cardiac dysfunction, with left ventricular ejection fraction (LVEF) ≥ 50%; Organ function levels must meet the protocol-specified requirements; Urine protein ≤ 1+ or < 1000 mg/24 h; For premenopausal women of childbearing potential, a pregnancy test (serum) must be performed within 7 days before starting treatment, and pregnancy must be ruled out; patients must not be lactating. All enrolled patients (regardless of sex) must use adequate barrier contraception throughout the entire treatment period and for 7 months after the end of treatment.排除标准:Exclusion Criteria:
Received surgery, radical radiotherapy, or immunotherapy within 4 weeks before the first dose; Prior exposure to ADC drugs with topoisomerase I inhibitor payload; Prior treatment with other T-cell receptor-targeting agents (excluding PD-1/PD-L1); Use of immunomodulators within 14 days before the first study drug dose; History of severe cardiac or cerebrovascular disease; Receiving chronic systemic corticosteroids at >10 mg/day prednisone before the first dose; Active autoimmune or inflammatory disease; Any thrombotic event within 6 months before randomization; Prolonged QTc, complete left bundle branch block, or similar; Active malignancy diagnosed within 3 years before randomization; Hypertension uncontrolled by two antihypertensives; Poorly controlled diabetes/hyperglycemia; History of steroid-treated ILD/interstitial pneumonitis; Concurrent lung disease causing clinically significant respiratory impairment; Active CNS metastases; Severe infection within 4 weeks before randomization; Massive or symptomatic serosal effusion; Severe non-healing wound, ulcer, or fracture within 4 weeks before consent; Clinically significant bleeding or bleeding tendency within 4 weeks before consent; Inflammatory bowel disease, extensive bowel resection, immune enteritis, bowel obstruction, or chronic diarrhea; Allergy or contraindication to the study drug; History of autologous/allogeneic stem cell transplantation; HIV antibody positive, active HBV, or active HCV; History of severe neurological or psychiatric illness; Received or planning to receive live vaccine within 28 days before randomization; Other conditions rendering the patient unsuitable per investigator's judgment.
引自 ClinicalTrials.gov, NCT07729956, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07729956,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。